- Home
- RGLS vs ACET Comparison
RGLS vs ACET Comparison
Compare RGLS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- ACET
- Stock Information
- Founded
- RGLS 2007
- ACET 1947
- Country
- RGLS United States
- ACET United States
- Employees
- RGLS N/A
- ACET N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RGLS Health Care
- ACET Health Care
- Exchange
- RGLS Nasdaq
- ACET Nasdaq
- Market Cap
- RGLS 106.7M
- ACET 110.4M
- IPO Year
- RGLS 2012
- ACET N/A
- Fundamental
- Price
- RGLS $1.48
- ACET $1.53
- Analyst Decision
- RGLS Strong Buy
- ACET Strong Buy
- Analyst Count
- RGLS 6
- ACET 4
- Target Price
- RGLS $10.33
- ACET $5.67
- AVG Volume (30 Days)
- RGLS 263.0K
- ACET 490.0K
- Earning Date
- RGLS 11-07-2024
- ACET 11-06-2024
- Dividend Yield
- RGLS N/A
- ACET N/A
- EPS Growth
- RGLS N/A
- ACET N/A
- EPS
- RGLS N/A
- ACET N/A
- Revenue
- RGLS N/A
- ACET N/A
- Revenue This Year
- RGLS N/A
- ACET N/A
- Revenue Next Year
- RGLS N/A
- ACET N/A
- P/E Ratio
- RGLS N/A
- ACET N/A
- Revenue Growth
- RGLS N/A
- ACET N/A
- 52 Week Low
- RGLS $1.08
- ACET $1.05
- 52 Week High
- RGLS $3.79
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- RGLS 44.54
- ACET 55.73
- Support Level
- RGLS $1.47
- ACET $1.42
- Resistance Level
- RGLS $1.65
- ACET $1.51
- Average True Range (ATR)
- RGLS 0.11
- ACET 0.07
- MACD
- RGLS -0.00
- ACET 0.01
- Stochastic Oscillator
- RGLS 15.79
- ACET 86.67
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.